To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound☆
Received 15 February 2006; received in revised form 18 April 2006; accepted 20 April 2006.
Refers to erratum:
Erratum to “To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound” [European Journal of Cancer, 42 (2006) 2472–2479]
Michele Lamuraglia, Bernard Escudier, Linda Chami, Brian Schwartz, Jérome Leclère, Alain Roche, Nathalie Lassau
European Journal of Cancer
May 2007 (Vol. 43, Issue 8, Page 1336) Full Text |
Full-Text PDF (91 KB)
Abstract
Introduction
The objective of this study was to evaluate dynamic contrast-enhanced Doppler ultrasound (DCE-US) with perfusion software (Vascular Recognition Imaging) and contrast agent injection as a predictor of tumour response, progression-free survival (PFS) and overall survival (OS).
Patients and methods
Thirty patients with a metastatic renal cell carcinoma (RCC) already enrolled in a double-blind randomised study were evaluated. Examinations were performed at baseline, and after 3 and 6weeks on sorafenib or a placebo in patients with tumour targets that were accessible to DCE-US.
Results
A total of 85 examinations were performed, 30 at baseline, 28 at 3weeks and 27 at 6weeks. The combination of a decrease in contrast uptake exceeding 10% and stability or a decrease in tumour volume allowed us to discriminate seven good responders and 20 poor responders at 3weeks. There was a statistically significant difference in PFS (p=10−4) and OS (p=10−4) between good and poor responders.
Conclusion
DCE-US is a new noninvasive imaging technique which might be an effective tool for evaluating antiangiogenic drugs in renal cancer.
ABSTRACT